Biosimilar Red Tape Elimination Act

The Biosimilar Red Tape Elimination Act, HR5526, was introduced in the House on September 19, 2025, and subsequently referred to the House Committee on Energy and Commerce. This bill aims to amend Section 351(k) of the Public Health Service Act to automatically deem a biological product licensed under this subsection as interchangeable with its reference product. This change would eliminate the current separate regulatory pathway required for biosimilar products to achieve interchangeability, a designation that allows pharmacists to substitute a biosimilar for its reference biologic without prescriber intervention. This bill does not authorize or appropriate any specific funding. Its mechanism of impact is regulatory, by altering the requirements for biosimilar interchangeability. The direct effect would be to streamline the market entry and adoption of biosimilar products. This regulatory change would reduce the market exclusivity period for innovator biologic manufacturers by facilitating quicker and broader market penetration for biosimilars. Conversely, it would increase the market share potential for biosimilar producers by removing a significant regulatory hurdle. Structural losers under this proposed legislation would be innovator biologic manufacturers that currently benefit from the extended market exclusivity provided by the existing interchangeability pathway. Companies such as Amgen ($AMGN), Johnson & Johnson ($JNJ), and Biogen ($BIIB) are examples of firms with significant portfolios of innovator biologics. Structural winners would be biosimilar manufacturers, including Viatris ($VTRS) and Teva Pharmaceutical Industries Limited ($TEVA), which stand to gain increased market access and competition against reference products. Amgen, Johnson & Johnson, and Biogen have seen recent declines in their stock prices, with Amgen down 1.84% in 7 days and 6.81% in 30 days, Johnson & Johnson down 0.63% in 7 days, and Biogen down 8.12% in 7 days and 8.37% in 30 days. In contrast, Viatris is up 3.47% in 7 days, and Teva is up 5.19% in 7 days, though both have seen 30-day declines. As of April 7, 2026, the bill is in the early stages of the legislative process, having only been referred to committee. There is a related Senate bill, S1954, which is also titled the Biosimilar Red Tape Elimination Act and has been referred to the Senate Committee on Health, Education, Labor, and Pensions. The existence of a companion bill indicates a coordinated effort to advance this policy, but both bills have significant legislative steps remaining, including committee hearings, potential amendments, committee votes, and floor votes in both chambers before they could be sent to the President for signature.